此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Contribution of Wine Components on Hydroxytyrosol Body Concentrations and Biological Effects

2014年7月23日 更新者:Parc de Salut Mar

Hydroxytyrosol as an Endogenous and Natural Antioxidant: Modulation by Alcohol Intake. Substudy 2. To Establish the Contribution of Wine Components on Hydroxytyrosol Body Concentrations and Biological Effects

The study is aimed at establishing the contribution of wine components on hydroxytyrosol body concentrations and biological effects.

研究概览

研究类型

介入性

注册 (实际的)

40

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Barcelona、西班牙、08003
        • Parc de Salut Mar

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 55年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Understanding and accepting the study procedures and signing the informed consent.
  • Male and female volunteers aged 18 to 55 years. No fixed sex ratio has been established.
  • Clinical history and physical examination demonstrating no organic or psychiatric disorders.
  • The ECG and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically.
  • The body mass index (BMI=weigh/height2) will range from 19 to 25 kg/m2, and the weight from 50 to 100 kg. 25-27 could be accepted.
  • Women with regular menstrual cycle of 26-32 days.
  • Subjects socially drinking and who had ingested wine at least once.

Exclusion Criteria:

  • Not meeting the inclusion criteria.
  • History or clinical evidence of gastrointestinal, liver, renal or other disorders which may lead to suspecting a disorder in drug absorption, distribution, metabolism or excretion, or that suggest gastrointestinal irritation due to drugs.
  • History or clinical evidence of psychiatric disorders, alcoholism, drug abuse, or regular use of psychoactive drugs.
  • Blood donation in the previous 8 weeks or participation in other clinical trials with drugs in the previous 12 weeks.
  • Having suffered any organic disease or major surgery in the three months prior to the study start.
  • Subjects with intolerance or serious adverse reactions to ethanol.
  • Regular use of any drug in the month prior to the study sessions, except for vitamins or diet supplements, that, in the opinion of the principal investigator or co-investigators designated by him, do not involve a risk for the subject and do not interfere with the study objectives. In this case they should be discontinued from one week before the experimental sessions to the end of them. The treatment with single or limited doses of symptomatic medicinal products in the week prior to the study sessions will not be a reason for exclusion if it is calculated that it has been cleared completely the day of the experimental session.
  • Taking more than 20 g of alcohol a day in women and more than 30 g in men.
  • Taking more than 5 coffees, teas, cola drinks or other stimulating drinks or with xanthines daily in the 3 months prior to the study start.
  • Subjects unable to understand the nature, consequences of the study and the procedures requested to be followed.
  • Smokers or ex-smokers of less than one year.
  • Subjects with positive serology to Hepatitis B, C or HIV.
  • Pregnant or nursing women or positive pregnancy test in urine. Women not undertaking to follow reliable contraceptive measures during the study (such as abstinence, hormonal contraceptives, intrauterine devices, double-barrier methods or vasectomised partner).
  • Women with amenorrhea or premenstrual syndrome of moderate or severe intensity.
  • Nonsteroidal anti-inflammatory drugs, antioxidants or vitamins consumption in the last 2 weeks.
  • Total cholesterol >6.00 mmol/l (240 mg/dl) or triglycerides >2.26 mmol/l (200 mg/dl).
  • Vegetarians or subjects following aberrant diets.
  • Physical exercise of >2h/day or >3000 kcal /week.

To be eligible, the subjects must agree to follow a poor polyphenols diet in the 72 hours prior to the start of each session and until 24 hours after.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:Water
Lemon-flavored water. 293 ml in pilot A, 147 ml in pilot B, 235 ml in pilot C, 147 ml in the definitive study.
Lemon-flavored water
有源比较器:Alcoholized wine

Wine 13º in pilot A (293 ml), B (147 ml) and the definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and 15 g of ethanol in the definitive study.

Wine 8º in pilot C (235 ml). Corresponding to 15 g of ethanol.

Wine 13º or wine 8º
安慰剂比较:De-alcoholized wine
Wine 0º. Pilot A: 293ml; pilot B: 147 ml; pilot C: 235 ml; definitive study: 147 ml. Corresponding to 0 g of ethanol.
Wine 0º
有源比较器:Ethanol

Ethanol 13º in pilot A (293 ml), B (147 ml) and definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and in the definitive study.

Ethanol 8º in pilot C (235 ml). Corresponding to 15 g of ethanol.

Ethanol was administered as a single dose of Vodka Absolut (40º) diluted in lemon-flavored water.

Vodka Absolut

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
羟基酪醇生物体液浓度
大体时间:给药后0-24小时
血浆和尿液中的羟基酪醇浓度
给药后0-24小时

次要结果测量

结果测量
措施说明
大体时间
主观醉酒
大体时间:给药后0-6h
使用视觉模拟量表测量乙醇的主观影响
给药后0-6h
乙醇浓度
大体时间:给药后0-6h
乙醇血液浓度
给药后0-6h
乙醇代谢物浓度
大体时间:给药后0-24小时
尿液中乙醇代谢物的回收
给药后0-24小时
多巴胺代谢物浓度
大体时间:给药后0-24小时
尿液中多巴胺代谢物的回收
给药后0-24小时
Vital signs
大体时间:0-24h after administration
Blood pressure, oral temperature and heart rate
0-24h after administration
Oxidation biomarkers of proteins and lipids
大体时间:0-24h after administration
0-24h after administration
Psychomotor performance (DSST)
大体时间:0-6h after administration
Psychomotor performance assessed by means of Digit symbol substitution test (DSST)
0-6h after administration
Gene expression of genes related with receptors and regulators/oxidative stress and antioxidant defence
大体时间:Baseline
Baseline
Platelets monoamine oxidase-B activity
大体时间:Baseline
Baseline
Breath ethanol
大体时间:30 min after administration
Breath ethanol concentration
30 min after administration

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

合作者

调查人员

  • 首席研究员:Magí Farré, MD, PhD、Parc de Salut Mar

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2011年5月1日

初级完成 (实际的)

2013年9月1日

研究完成 (实际的)

2013年9月1日

研究注册日期

首次提交

2013年2月11日

首先提交符合 QC 标准的

2013年2月11日

首次发布 (估计)

2013年2月13日

研究记录更新

最后更新发布 (估计)

2014年7月24日

上次提交的符合 QC 标准的更新

2014年7月23日

最后验证

2014年7月1日

更多信息

与本研究相关的术语

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

Water的临床试验

3
订阅